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Summary 
An isocratic high pressure liquid chromatographic system was developed for the 
estimation of purine nucleosides and oxypurines in blood. Use was made of a 
reversed-phase column. Nucleotides derived from erythrocytes affected the separa- 
tion; these compounds were removed with A120,. The recovery of the whole 
clean-up procedure exceeded 75%, and the lower detection limit of the assay for 
blood metabolites was 0.1 pmol/l. In 6 healthy volunteers, non-resting, the follow- 
ing blood concentrations (mean values t S.D. in pmol/l) were observed: adenosine 
(-c 0.1) inosine (0.2 + O.l), hypoxanthine (2.2 & 1.3) and xanthine (0.2 -+ 0.1). In 
plasma and serum the total amount of these compounds was 1.9 and 5.4 times 
higher, respectively, presumably due to nucleotide breakdown during blood process- 
ing. The myocardial arterial-venous differences of blood purine nucleosides, 
oxypurines and lactate were subsequently measured in blood samples from 13 
patients with angiographically documented ischemic heart disease, undergoing an 
atria1 pacing stress test. No significant release of adenosine, inosine and xanthine by 
the heart was detectable in this study. The myocardial arterial-venous difference of 
lactate changed from 0.01 5 0.03 mmol/l (mean * SEM) at rest, to -0.10 -+ 0.04 
mmol/l during pacing (p < 0.002). Relatively larger changes were observed for 
hypoxanthine: pacing increased the arterial-venous difference from - 0.01 -+ 0.05 to 
- 0.5 1 -+ 0.17 pmol/l ( p < 0.02). We conclude that the high pressure liquid chro- 
matographic assay of blood hypoxanthine is a useful tool in the diagnosis of 
ischemic heart disease. 
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Introduction 
During and after hypoxia or ischemia, there is in the heart, as well as in other 
muscles, excessive ATP breakdown. This degradation of ATP causes an efflux of 
breakdown products, which are able to pass through the cell membrane, and are 
released into the blood. The purine derivatives adenosine, inosine and hypoxanthine 
are thought to be markers for ischemia (for a review, see ref. [l]). Because of high 
activities of adenosine deaminase (EC 3.5.4.4; ADA) and nucleoside phosphorylase 
(EC 2.4.2.1; NP), and low or non-detectable amounts of xanthine oxidase (EC 
1.2.3.2; X0) in the heart and blood, hypoxanthine seems very promising as marker 
for myocardial ischemia [2,3]. Enzymatic purine determinations [4,5] are time- 
consuming and do not differentiate between hypoxanthine and xanthine. Recently 
high pressure liquid chromatography (HPLC) came into use for the determination of 
nucleosides and purine bases in urine, plasma and serum [6-81. We have developed a 
method to determine these compounds in blood, and have compared the levels of 
adenosine, inosine, hypoxanthine and xanthine in blood, plasma and serum. With 
the assay we demonstrated the myocardial release of hypoxanthine in patients with 
angiographically documented ischemic heart disease, undergoing an atria1 pacing 
stress test. 
Materials and methods 
Enzymes (X0, 13 U/ml; NP, 10 U/ml; ADA, 140 U/ml) were purchased from 
Boehringer-Mannheim, F.R.G.; CH,OH (Uvasol), NH,H,PO,, KOH, K,CO,, 
adenosine, hypoxanthine and uridine from Merck (Darmstadt, F.R.G.). Uric acid 
was supplied by Sigma (Saint Louis, MO, U.S.A.), and the other standards by 
Koch-Light (Colnbrook, Bucks., U.K.). Al,O, came from Desaga, Heidelberg, 
F.R.G. [U-‘4C]nucleosides and oxypurines were obtained from The Radiochemical 
Centre (Amersham, Bucks., U.K.; spec. act. 50-60 Ci/mol). HClO, was supplied by 
Merck, and used as a 1.3 mol/l dilution. Water was purified with the Milli- 
Ro4/Milli-Q system (Millipore Co., Bedford, MA, U.S.A.). 
Blood sample treatment 
Blood (2.0 ml) was deproteinized immediately with an equal volume of HClO, as 
described by Remme et al. [2]. Plasma was prepared by adding 3 ml blood to a 
heparinized tube and immediate centrifugation for 15 min at 3000 X R (4°C). Serum 
was prepared from 3 ml blood which had been allowed to clot at room temperature 
for 30 min and subsequent centrifugation. Plasma and serum were also deproteinized 
with equal volumes of HClO,. After centrifugation, the supernatant fluids were 
stored at -20°C. The acid extracts were brought to pH 5-7 at 0°C with an 
automatic titration device (Radiometer, Copenhagen) using 150&200 ~1 6 mol/l 
KOH + 1 mol/l K,CO,. KClO, was spun down for 10 n-tin at 12000 X g at 4°C. For 
plasma and serum 200 ~1 of these extracts were directly injected onto the HPLC 
column. For whole blood extracts, removal of nucleotides appeared to be necessary. 
We used the method of Chatterjee et al. [9], with some minor differences. We applied 
1.5 ml of the deproteinized, neutralized blood sample onto a pre-washed column of 
Al,O, (0.6 g) in a Pasteur pipette, and eluted it with 5.0 ml 10 mmol/l Tris/HCl, 
pH 7.4. For faster elution, a vacuum was applied; with a 1225 sampling manifold 
(Millipore Co.) 12 samples were treated at the same time. With standards (about 10 
pmol/l oxypurines and nucleosides, and about 5 mmol/l nucleotides), we found 
recoveries exceeding 90%, whereas the nucleotides were fully retained. These values 
are in close agreement with values in the literature [9]. 
Recovev studies for blood treatment 
To carry out recovery studies, it is necessary to inactivate first the purine 
metabolizing enzymes in the blood. We achieved this by rapid mixing of blood with 
cold HClO,. This procedure is comparable to the determination of recoveries after 
inactivation of enzymes by freeze-clamping heart tissue, or removal of cells from 
blood, and subsequent addition of standards [4,5,7,8,10- 121. If radioactive standards 
were used 10 ~1 14C-labelled hypoxanthine, xanthine, inosine or adenosine were 
mixed with 10 ml HClO,. For the determination of radioactivity 50 ~1 aliquots were 
mixed with 10 ml Insta-gel (Packard Instr. Co., Downers Grove, IL. U.S.A.) and 
counted with a Packard Tricarb 2650 liquid scintillation counter. 
High pressure liquid chromatography 
A Varian 8520 high pressure liquid chromatograph (Varian, Palo Alto, CA, 
U.S.A.) was used with a pneumatic sampling device (Valco Instr. Co., Houston, TX, 
U.S.A.), an autosampler (Varian), a Model 440 fixed wavelength UV-detector 
(Waters Assoc., Milford, MA, U.S.A.) and a chromatographic data system C-l 11 
(Varian). A 4 mm I.D. X 30 cm prepacked pBondapak/C ,8 column (Waters Assoc.) 
was used in these studies. The packing material has an average particle size of 10 pm 
and consists of porous silica to which a monolayer of octadecyltrichlorosilane is 
chemically bound. Chromatographic conditions were adapted from earlier work [ 131: 
200 ~1 samples were eluted from this column with 10 mmol/l NH,H,PO,/CH,OH 
(10 : 1, v/v), pH 5.50. The flow rate was 60 ml/h ( p = 80 bar). 
Lactate assay 
Lactate was determined in acid supernatants in duplicate with an AutoAnalyzer 
II (Technicon, Tarrytown, NY, U.S.A.) as described by Apstein et al. [ 141. 
Statistical analysis 
Statistical analysis in Table II was performed with a two-group comparison test 
based on Student’s t distribution, and those in Table III and Fig. 5 by Student’s 
paired t test. p-values < 0.05 (two-sided) were considered significant. 
Results 
HPLC 
Fig. 1 represents the separation of several nucleosides and purine bases. The lower 
detection limit with a 200 ~1 sample loop is 0.01 pmol/l; the method is linear up to 
76 
200 pmol/l (Fig. 2). The standard deviation at the 10, 1 and 0.1 pmoljl level is 
< 0.1256, < 5% and < 9%, respectively (n = 9). Identification of the compounds in 
pre-purified blood samples was achieved by retention times (Fig. 3a), co- 
chromatography of standards (Fig. 3b) and enzyme shifts (Fig. 3c), as described by 
Hartwick et al. [7]. The clean-up procedure of the blood samples causes a 9-fold 
dilution, which increased the lower detection limit in blood to 0.1 ~mol/l. 
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Fig. I. Isocratic HPLC separation of nucleosidea and purine bases (2-4 pmol/l). Column: PBondapak 
C,, (4X300 mm). Buffer: IO mmol/l NH,H,PO,/CH,OH (IO: I, v/v). pH 5.50. Flow rate: 60 ml/h. 
InJected sample volume: 200 ~1. I, uric acid: 2. uracil: 3. uridine: H, hypoxanthine; X, xanthine; 4. 
xanthosine; I. inosine: 5. guanosine: 6, adenine: A, adenosine. 
Recoveries 
With radioactive standards the recoveries for the whole clean-up procedure 
exceeded 75% (Table I). With non-radioactive standards, assayed by HPLC, we 
found comparable recoveries in the concentration range of our interest (Fig. 4). 
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Fig. 2. Calibration curves for HPLC of hypoxanthine (0 - 0) ~=2.16x-0.09, r= 1.000; xanthine 
(-0) y=0.73x+0.01, r=0.999: inosine (m -D) J= 1.59.x+0.02, r= 1.000; adcnosine 
(O- 0) ~=2.23x-0.05, r=0.999. 
Purine derivatives in blood, plasma and serum 
Six healthy non-fasting, non-resting volunteers donated venous blood. In their 
blood, plasma and serum, hypoxanthine, xanthine, inosine and adenosine were 
TABLE I 
RECOVERY OF PURINE NUCLEOSIDES AND OXYPURINES DURING SAMPLE PREPARA 
TION 
(Data represent mean values of 6 experiments+ S.E.M.) 
Clean-up stage Adenosine Inosine Hypoxanthine Xanthine 
dpm added 
Acidified human blood (= 100%) 50000 330000 230000 44000 
recovery (%) 
Acid supematant 9623 106tl IOI? I 93’4 
Neutralized extract 88k2 101 k-2 9222 9924 
Alumina eluate 79k2 91 f4 862 I 1626 
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Fig. 3 (a, b and c). Chromatogram of blood from a normal donor. (a) Blood was dcprotcinizcd and 
purified as described under “Materials and methods”. Conditions. see Fig. I. (The upper panel represents 
the same chromatogram with a 4 times lower detector sensitivity.) H. hypoxanthine; X. xanthine; I. 
inosinc; A. adenosine. 
TABLE II 
CONCENTRATION OF ADENOSINE. INOSINE AND (HYPO)XANTHINE IN HUMAN BLOOD. 
PLASMA AND SERUM 
(Data represent mean values in pmol/l of 5-6 voluntccrs~SD.) 
Preparation Adenosine Inosine 
(pmol/I) (PmoVl) 
Hypoxanthinc 
(pmol/l) 
Xanthinc 
(pmol/I) 
Blood 
Plasma 
Serum 
CO.1 0.220.1 2.22 1.3 0.2+-0.1 
co.1 0.2-to.2 3.620.8 1.1 kO.7 * 
0.9F0.2 *. l.OiO.4 *. 5.6& I.9 * 6.6i2.1 *. 
* p<0.05 VS. blood, A ~(0.05 vs. plasma 
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Fig. 3(b). Chromatogram as in (a). after co-injection of a solution containing hypoxanthine. xanthine. 
inosine and adcnosine. 
determined. The results are listed in Table II. As can be seen plasma shows 1.6 times 
higher levels of hypoxanthine and 5.5 times higher levels of xanthine than blood. 
Serum has significantly higher values of the AMP-catabolites. Here the values are 2.5 
times (for hypoxanthine) to 33 times (for xanthine) higher, compared to blood. 
Determination of blood purine nucleosides, oxypurines and lactate of patients with 
ischemic heart disease 
Thirteen patients with angina pectoris were catheterized as described by Remme 
et al. [2]. The patients were fasted overnight and 36 h before catheterization all 
medication was stopped. Before catheterization 50000 IE of heparin were infused. 
The diagnosis, ischemic heart disease, was established by angiography (obstruction 
of at least one coronary artery > 50%). Before angiography an atria1 pacing stress 
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Fig. 3(c). Chromatogram as in (a), after 30 min incubation with X0. NP and ADA. 5 pl each 
test was performed. During a control period, maximal pacing, and 5 and 20 min 
after pacing, arterial and coronary sinus blood samples were taken. At rest no 
significant myocardial arterial-venous hypoxanthine or lactate difference was seen 
(Fig. 5). During maximal pacing, a rise in coronary sinus hypoxanthine (from 0.83 to 
1.43 pmol/l, p < 0.01) and lactate (from 0.87 to 0.98 mmol/l, p < 0.005) was 
observed, which fell off after pacing. The arterial levels of these compounds 
remained constant. The myocardial arterial-venous difference of hypoxanthine 
changed from -0.01 pmol/l at rest to -0.5 1 pmol/l ( p < 0.02) during pacing 
(Table III). We showed in earlier work [2,15] that patients with angina1 pain, but 
with patent coronary arteries (< 50% obstruction), did not produce myocardial 
hypoxanthine. Relatively smaller changes were observed for lactate: pacing in- 
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Fig. 4. Recoveries determined by HPLC. Standards were dissolved in HCIO,, before blood was added. 
Hypoxanthine: (0 - O),r=O.72.~+0.77, r=0.997; xanthine: (O- l ),r=O.6Xx+O.Ol.r=0.999: 
inosine: ( n - n )y=0.72xp0.03, r=0.993; adenosine: (O- q )~~=0.77.x+O.20. r=0.995. For 
conditions, see legends to Figs. I and 3. 
Fig. 5. Arterial (0 - 0) and coronary sinus (O- 0) hypoxanthine and lactate levels during an 
atrial pacing stress test of I3 patients with ischemic heart disease. C,, control period; P,, maximal pacing: 
C, and C,. 5 and 20 min after maximal pacing, respectively. Mean values are given with I S.E.M. 
(* pcO.05 vs. arterial levels). 
TABLE III 
MYOCARDIAL ARTERIAL-VENOUS DIFFERENCES AND EXTRACTION VALUES OF HYPO- 
XANTHINE AND LACTATE DURING AN ATRIAL PACING STRESS TEST OF PATIENTS 
WITH ISCHEMIC HEART DISEASE 
The extraction value is defined as the arterial concentration minus coronary sinus concentration divided 
by the arterial concentration, times 100%. Mean values are given& S.E.M. (II= 13). 
Heart rate Hypoxanthine Lactate 
(beats/min) 
A-CS Extraction A-CS Extraction 
(pmol/l) (CJ,) (mmol/l) (X) 
C, 79t4 PO.01 kO.05 -62 6 0.01 -t 0.03 4k4 
PI 14424 * -0.51 kO.17 * -68218 * -0.lOt0.04 * -926 * 
C, 7x24 -0.33io.14 * -492 14 * 0.08 i 0.03 131-6 
C, 8024 -0.15~0.08 -35k 14 0.12t0.04 * 19i6 * 
* pco.05 vs. c,. 
A - CS, arterial-venous difference; C,, control period; P,. maximum pacing: CL. 5 min after pacing: C,. 
20 min after pacing. 
creased the arterial-venous difference from 0.01 to -0.10 mmol/l ( p < 0.002, see 
Table III). Significant production of lactate, calculated either as arterial-venous 
difference or extraction, only took place during maximal pacing, but significant 
hypoxanthine release was also present 5 min after pacing was stopped (Table III). 
The coronary sinus levels of adenosine, inosine and xanthine during the control 
period were 0.17 -+ 0.04, 0.53 ? 0.11 and 0.20 k 0.14 pmol/l, respectively. No 
significant arterio-venous differences were observed throughout the test. 
Discussion 
Hypoxanthine, xanthine, inosine and adenosine levels in human blood (or plasma 
or serum) have been measured in normal adults [7- 11,161, patients with gout [ 171, 
immunological disorders [ 181, ischemic heart disease [2,3.19,20]. pregnant women 
[2 11, and children [2 11. The values reported show considerable variation, which could 
be caused by: 
(1) Differences in assay methods. The enzymatic determination of hypoxanthine, 
for instance, does not differentiate between hypoxanthine and xanthine. 
(2) As we have shown in Table II, large differences occur in the levels of these 
compounds when these are measured in blood, plasma or serum from the same 
person. These differences can be explained by the enzymatic degradation of ATP, 
derived from blood cells. and ADP, released from platelets during clotting [7,8]. 
Furthermore xanthine, as the end-product of guanine nucleotide catabolism, can be 
expected to occur in higher concentrations in plasma and serum than in blood. For 
instance, blood xanthosine, guanosine and guanine are rapidly converted to xanthine 
[22]. For this reason instant inactivation by acid seems indicated, when one wants to 
determine the nucleoside and oxypurine concentration in the blood. 
(3) Physical activity also influences the levels of these AMP catabolites in blood. 
Sutton et al. [23] showed that the plasma levels of oxypurines are twice as high 
during and after physical training compared with control levels. Although they did 
not measure inosine levels in the plasma, urinary inosine during excercise is elevated 
tenfold, possibly indicating increased inosine levels in the blood. Therefore, if one 
wants to measure normal values, it is also important to define the physical state of 
the group under study. 
We feel that measuring myocardial arterial-venous differences of blood hypo- 
xanthine levels could give insight into the metabolic state of the heart; the method 
described here makes it possible to measure a number of purine metabolites in 
blood. The observations on the patients undergoing an atria1 pacing stress test 
indicate that hypoxanthine is a more sensitive parameter for myocardial ischemia 
than adenosine, inosine, xanthine or lactate, because hypoxanthine release is more 
pronounced and of a longer duration than that of the other compounds. 
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